Hepatotoxicity, or drug-induced liver injury (DILI), is one of the most common causes of acute liver failure in the developed world and a leading reason for drug development failure and post-marketing withdrawal. The liver is uniquely susceptible to toxic injury because of its central role in drug metabolism, its high blood flow, and its location as the first organ exposed to substances absorbed from the gastrointestinal tract. DILI can mimic virtually every form of naturally occurring liver disease and ranges from asymptomatic transaminase elevations to fulminant hepatic failure requiring transplantation.
Mechanisms of injury in hepatotoxicity are broadly classified as intrinsic or idiosyncratic. Intrinsic hepatotoxicity is dose-dependent and predictable, occurring in a high proportion of exposed individuals when sufficient doses are reached. Paracetamol (acetaminophen) overdose exemplifies intrinsic hepatotoxicity: a toxic metabolite, NAPQI, depletes hepatic glutathione and covalently binds to cellular proteins, causing centrilobular necrosis. Idiosyncratic hepatotoxicity is unpredictable, dose-independent, and occurs in only a small fraction of exposed individuals. It is often immune-mediated or linked to genetic polymorphisms in metabolic enzymes. Isoniazid, valproic acid, and amoxicillin-clavulanate are well-known causes of idiosyncratic DILI.
The pattern of liver injury is typically categorized as hepatocellular, cholestatic, or mixed. Hepatocellular injury is characterized by predominant elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), reflecting direct damage to hepatocytes. Paracetamol, isoniazid, and statins produce hepatocellular patterns. Cholestatic injury presents with elevations in alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) due to impaired bile flow, as seen with anabolic steroids, chlorpromazine, and amoxicillin-clavulanate. Mixed patterns involve elevations of both aminotransferases and cholestatic enzymes. Determining the pattern of injury helps identify the causative agent and guides prognosis.
Causative agents encompass a diverse range of medications and supplements. Paracetamol is the most common cause of acute liver failure in many countries. Isoniazid, a first-line antituberculosis agent, causes hepatotoxicity in up to 2 percent of patients, particularly in older adults and slow acetylators. Statins produce asymptomatic transaminase elevations in approximately 1 to 3 percent of users, though clinically significant liver injury is rare. Chronic alcohol consumption causes steatohepatitis, fibrosis, and cirrhosis through direct hepatocyte toxicity, oxidative stress, and immune activation. Herbal and dietary supplements, including kava, green tea extract, and anabolic steroids, are increasingly recognized causes of DILI.
Clinical presentation varies by the mechanism and severity of injury. Acute hepatotoxicity may present with nausea, vomiting, right upper quadrant pain, jaundice, dark urine, and coagulopathy. Severe cases progress to hepatic encephalopathy, cerebral edema, and multisystem organ failure. Chronic injury may be asymptomatic for years, with subtle elevations in liver enzymes detected incidentally on routine laboratory testing. The combination of jaundice and elevated aminotransferases — known as Hy’s Law — predicts a high risk of fatal liver injury and warrants immediate discontinuation of the suspected agent.
Diagnosis and monitoring rely upon serial measurement of liver enzymes, bilirubin, and coagulation parameters. A detailed medication history, including over-the-counter drugs, supplements, and herbal products, is essential. The R ratio — the ratio of ALT to ALP elevations — helps distinguish hepatocellular from cholestatic patterns. Liver biopsy is reserved for cases where the diagnosis remains uncertain. Routine monitoring of liver function is recommended for patients on known hepatotoxic drugs, with the frequency determined by the agent’s risk profile.
Prevention and management begin with identifying and discontinuing the offending agent. N-acetylcysteine is the specific antidote for paracetamol hepatotoxicity and is most effective when administered within eight to ten hours of overdose. Supportive care includes fluid resuscitation, nutritional support, and management of complications such as coagulopathy and encephalopathy. Liver transplantation may be required for patients who progress to acute liver failure despite maximal medical management. Preventive strategies include appropriate dosing, avoidance of concurrent hepatotoxic agents, and patient education about the signs of liver injury.
